Lion Point Capital
Latest statistics and disclosures from Lion Point Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MLYS, MIST, FENC, JSPR, AVDL, and represent 32.99% of Lion Point Capital's stock portfolio.
- Added to shares of these 10 stocks: RPRX, JSPR, MLTX, KURA, CMPS, PRAX, DAWN, RCKT, MIST, MRSN.
- Started 9 new stock positions in DAWN, Spruce Biosciences, KURA, RCKT, PRAX, MRSN, RPRX, MLTX, CMPS.
- Reduced shares in these 9 stocks: MLYS, ARDX, KNSA, FENC, BBIO, INSM, AVDL, ARQT, Mersana Therapeutics.
- Sold out of its position in Mersana Therapeutics.
- Lion Point Capital was a net seller of stock by $-2.2M.
- Lion Point Capital has $18M in assets under management (AUM), dropping by 19.51%.
- Central Index Key (CIK): 0001643354
Tip: Access up to 7 years of quarterly data
Positions held by Lion Point Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Lion Point Capital
Lion Point Capital holds 27 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Mineralys Therapeutics (MLYS) | 8.4 | $1.5M | -50% | 39k | 37.92 |
|
| Milestone Pharmaceuticals (MIST) | 7.5 | $1.3M | +19% | 659k | 2.00 |
|
| Fennec Pharmaceuticals (FENC) | 6.5 | $1.2M | -37% | 123k | 9.36 |
|
| Jasper Therapeutics Com New (JSPR) | 5.4 | $949k | +172% | 399k | 2.38 |
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 5.2 | $912k | -39% | 60k | 15.27 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 5.2 | $909k | -49% | 23k | 38.83 |
|
| Insmed Com Par $.01 (INSM) | 5.1 | $900k | -41% | 6.3k | 144.01 |
|
| Ardelyx (ARDX) | 5.1 | $897k | -51% | 163k | 5.51 |
|
| Benitec Biopharma Com New (BNTC) | 4.9 | $870k | 62k | 14.03 |
|
|
| Syndax Pharmaceuticals (SNDX) | 4.8 | $846k | 55k | 15.38 |
|
|
| Royalty Pharma Shs Class A (RPRX) | 4.3 | $755k | NEW | 21k | 35.28 |
|
| Disc Medicine (IRON) | 4.0 | $700k | 11k | 66.08 |
|
|
| Bridgebio Pharma (BBIO) | 3.9 | $691k | -48% | 13k | 51.94 |
|
| Geron Corporation (GERN) | 3.9 | $685k | 500k | 1.37 |
|
|
| Arcutis Biotherapeutics (ARQT) | 3.8 | $665k | -23% | 35k | 18.85 |
|
| Regenxbio Inc equity us cm (RGNX) | 3.2 | $557k | 58k | 9.65 |
|
|
| Seres Therapeutics Com New (MCRB) | 3.0 | $522k | +59% | 27k | 19.24 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.7 | $484k | NEW | 68k | 7.17 |
|
| Kura Oncology (KURA) | 2.3 | $407k | NEW | 46k | 8.85 |
|
| Biohaven (BHVN) | 1.9 | $341k | 23k | 15.01 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 1.9 | $332k | NEW | 58k | 5.73 |
|
| Praxis Precision Medicines I Com New (PRAX) | 1.7 | $302k | NEW | 5.7k | 53.00 |
|
| Day One Biopharmaceuticals I (DAWN) | 1.7 | $296k | NEW | 42k | 7.05 |
|
| Rocket Pharmaceuticals (RCKT) | 1.6 | $280k | NEW | 86k | 3.26 |
|
| Mersana Therapeutics (MRSN) | 1.1 | $200k | NEW | 26k | 7.76 |
|
| Humacyte (HUMA) | 0.8 | $145k | 84k | 1.74 |
|
|
| Spruce Biosciences Com New | 0.1 | $9.0k | NEW | 1.0k | 8.95 |
|
Past Filings by Lion Point Capital
SEC 13F filings are viewable for Lion Point Capital going back to 2015
- Lion Point Capital 2025 Q3 filed Nov. 14, 2025
- Lion Point Capital 2025 Q2 filed Aug. 14, 2025
- Lion Point Capital 2025 Q1 filed May 15, 2025
- Lion Point Capital 2024 Q4 filed Feb. 14, 2025
- Lion Point Capital 2024 Q3 filed Nov. 14, 2024
- Lion Point Capital 2024 Q2 filed Aug. 14, 2024
- Lion Point Capital 2024 Q1 filed May 15, 2024
- Lion Point Capital 2023 Q4 filed Feb. 14, 2024
- Lion Point Capital 2023 Q3 filed Nov. 14, 2023
- Lion Point Capital 2023 Q2 filed Aug. 14, 2023
- Lion Point Capital 2023 Q1 filed May 15, 2023
- Lion Point Capital 2022 Q4 filed Feb. 14, 2023
- Lion Point Capital 2022 Q3 filed Nov. 14, 2022
- Lion Point Capital 2022 Q2 filed Aug. 15, 2022
- Lion Point Capital 2022 Q1 filed May 16, 2022
- Lion Point Capital 2021 Q4 filed Feb. 14, 2022